Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Analyst Recommendations
This is a summary of recent recommendations for Ernexa Therapeutics and Ocular Therapeutix, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Ocular Therapeutix | 1 | 1 | 12 | 0 | 2.79 |
Ocular Therapeutix has a consensus price target of $22.56, indicating a potential upside of 100.14%. Given Ocular Therapeutix’s stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Ernexa Therapeutics.
Volatility and Risk
Earnings & Valuation
This table compares Ernexa Therapeutics and Ocular Therapeutix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | $580,000.00 | 16.38 | -$44.54 million | ($3.01) | -0.40 |
| Ocular Therapeutix | $63.72 million | 37.68 | -$193.51 million | ($1.44) | -7.83 |
Ernexa Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 4.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Ernexa Therapeutics and Ocular Therapeutix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | -1,950.55% | -304.60% |
| Ocular Therapeutix | -447.57% | -86.33% | -57.29% |
Summary
Ocular Therapeutix beats Ernexa Therapeutics on 8 of the 14 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
